Δ133p53 isoform enhances TLR4 function to promote tumour growth
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumour protein 53 (TP53) isoforms like Δ133p53 promote cancer growth. Targeting cell surface proteins, such as toll-like receptor 4 (TLR4), offers a new strategy to inhibit Δ133p53-driven tumour progression and metastasis.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Tumour protein 53 (TP53) is a tumor suppressor frequently mutated in cancer.
- TP53 isoforms, including the Δ133p53 family, can paradoxically promote tumor growth and metastasis.
- Targeting Δ133p53 function presents a potential therapeutic strategy against cancer metastasis.
Purpose Of The Study
- To identify cell surface proteins involved in Δ133p53-mediated tumor promotion.
- To investigate the role of toll-like receptor 4 (TLR4) in Δ133p53-driven tumor progression.
- To evaluate the therapeutic potential of targeting cell surface changes in Δ133p53-expressing tumors.
Main Methods
- Characterization of cell surface protein expression in a mouse model with tumors expressing Δ122p53 (a Δ133p53 family member).
- Inhibition of cell surface trafficking and TLR4 signaling.
- Assessment of tumor growth and metastasis following therapeutic interventions.
Main Results
- Inhibition of cell surface trafficking reduced tumor growth and metastasis in the mouse model.
- Increased expression of toll-like receptor 4 (TLR4) and apoptosis inhibitor 5 was observed on the cell surface of Δ133p53/Δ122p53-expressing cells.
- Inhibition of TLR4 signaling was sufficient to decrease Δ122p53 tumor growth.
Conclusions
- Δ133p53 contributes to tumor progression by stimulating TLR4 function.
- Targeting cell surface protein alterations, specifically TLR4, can inhibit Δ133p53-mediated tumor promotion.
- These findings suggest novel therapeutic strategies for cancers with altered TP53 isoforms.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...